BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

944 related articles for article (PubMed ID: 15946497)

  • 1. [Molecular genetic and epigenetic mechanisms of hepatocarcinogenesis].
    Xue KX
    Ai Zheng; 2005 Jun; 24(6):757-68. PubMed ID: 15946497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.
    Edamoto Y; Hara A; Biernat W; Terracciano L; Cathomas G; Riehle HM; Matsuda M; Fujii H; Scoazec JY; Ohgaki H
    Int J Cancer; 2003 Sep; 106(3):334-41. PubMed ID: 12845670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.
    Su H; Zhao J; Xiong Y; Xu T; Zhou F; Yuan Y; Zhang Y; Zhuang SM
    Mutat Res; 2008 May; 641(1-2):27-35. PubMed ID: 18358501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer.
    Hussain SP; Schwank J; Staib F; Wang XW; Harris CC
    Oncogene; 2007 Apr; 26(15):2166-76. PubMed ID: 17401425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
    Marotta F; Vangieri B; Cecere A; Gattoni A
    Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocarcinogenesis: hepatitis viruses and altered tumor suppressor gene function.
    Tabor E
    Princess Takamatsu Symp; 1995; 25():151-61. PubMed ID: 8875620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 and liver carcinogenesis.
    Staib F; Hussain SP; Hofseth LJ; Wang XW; Harris CC
    Hum Mutat; 2003 Mar; 21(3):201-16. PubMed ID: 12619106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma.
    Peng CY; Chen TC; Hung SP; Chen MF; Yeh CT; Tsai SL; Chu CM; Liaw YF
    Anticancer Res; 2002; 22(2B):1265-71. PubMed ID: 12168936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma.
    Zhang YJ; Ahsan H; Chen Y; Lunn RM; Wang LY; Chen SY; Lee PH; Chen CJ; Santella RM
    Mol Carcinog; 2002 Oct; 35(2):85-92. PubMed ID: 12325038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of chromosomes 9p and 17 associated with abnormal expression of p53, p16/MTS1 and p15/MTS2 gene protein in hepatocellular carcinomas.
    Shao J; Li Y; Li H; Wu Q; Hou J; Liew C
    Chin Med J (Engl); 2000 Sep; 113(9):817-22. PubMed ID: 11776078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation framework of cell cycle gene inhibitors in cirrhosis and associated hepatocellular carcinoma.
    Roncalli M; Bianchi P; Bruni B; Laghi L; Destro A; Di Gioia S; Gennari L; Tommasini M; Malesci A; Coggi G
    Hepatology; 2002 Aug; 36(2):427-32. PubMed ID: 12143052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
    Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
    J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hepatocellular carcinoma: molecular biology aspects].
    Blum HE
    Zentralbl Chir; 1994; 119(11):759-63. PubMed ID: 7846955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.
    Koskinas J; Petraki K; Kavantzas N; Rapti I; Kountouras D; Hadziyannis S
    J Viral Hepat; 2005 Nov; 12(6):635-41. PubMed ID: 16255765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Alteration of p53 gene during tree shrews' hepatocarcinogenesis].
    Su JJ; Li Y; Ban KC; Qin LL; Wang HY; Yang C; Ou C; Duan XX; Li YY; Yan RQ
    Zhonghua Gan Zang Bing Za Zhi; 2003 Mar; 11(3):159-61. PubMed ID: 12681064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China.
    Fujimoto Y; Hampton LL; Wirth PJ; Wang NJ; Xie JP; Thorgeirsson SS
    Cancer Res; 1994 Jan; 54(1):281-5. PubMed ID: 7903205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain metastasis from hepatocellular carcinoma associated with hepatitis B virus.
    Frati A; Salvati M; Giarnieri E; Santoro A; Rocchi G; Frati L
    J Exp Clin Cancer Res; 2002 Sep; 21(3):321-7. PubMed ID: 12385572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B, aflatoxin B(1), and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies.
    Stern MC; Umbach DM; Yu MC; London SJ; Zhang ZQ; Taylor JA
    Cancer Epidemiol Biomarkers Prev; 2001 Jun; 10(6):617-25. PubMed ID: 11401911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis of hepatocellular carcinoma: a review from the viewpoint of molecular analysis.
    Kasai Y; Takeda S; Takagi H
    Semin Surg Oncol; 1996; 12(3):155-9. PubMed ID: 8727603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p53 mutation spectrum in hepatocellular carcinoma from Guangxi, China : role of chronic hepatitis B virus infection and aflatoxin B1 exposure.
    Qi LN; Bai T; Chen ZS; Wu FX; Chen YY; De Xiang B; Peng T; Han ZG; Li LQ
    Liver Int; 2015 Mar; 35(3):999-1009. PubMed ID: 24461059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.